Supernus Pharmaceuticals

SUPN

Market cap $2.47B

Overview Fund Activity

43.99 USD

0.00

0%

At close Updated Sep 16, 4:00 PM EDT

Pre-market

After hours

43.99

0.00

0%

1 day

0%

5 days

-4.37%

1 month

2.33%

3 months

35.48%

6 months

36.78%

Year to date

20.75%

1 year

39.74%

5 years

95.69%

10 years

115.11%

About: Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Employees: 674

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

5,108% more call options, than puts

Call options by funds: $677K | Put options by funds: $13K

51% more repeat investments, than reductions

Existing positions increased: 124 | Existing positions reduced: 82

18% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 33

0% more funds holding

Funds holding: 291 [Q1] → 292 (+1) [Q2]

0.26% more ownership

Funds ownership: 105.93% [Q1] → 106.19% (+0.26%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

3% less capital invested

Capital invested by funds: $1.94B [Q1] → $1.87B (-$63M) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$40

9% downside

Avg. target

$43

2% downside

High target

$46

5% upside

2 analyst ratings

1 positive

50%

1 neutral

50%

0 negative

0%

Piper Sandler David Amsellem	$40	Neutral Maintained	29 Aug 2025
Cantor Fitzgerald Kristen Kluska	$46	Overweight Maintained	6 Aug 2025

See Analyst Rankings

Financial journalist opinion

Supernus Pharmaceuticals to Participate in September Investor Conferences

ROCKVILLE, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today management will participate in the following September investor conferences: Cantor Global Healthcare Conference Date:Fireside chat:Place: Wednesday, September 3, 2025 8:00 a.m.

Supernus Pharmaceuticals to Participate in September Investor Conferences

Zacks Investment Research

Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks Investment Research

Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.36 per share a year ago.

Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates

Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call Transcript

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Jack A. Khattar - Founder, President, CEO, Secretary & Director Timothy C.

Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call Transcript

Supernus Announces Second Quarter 2025 Financial Results

ROCKVILLE, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the second quarter 2025 and associated Company developments.

Supernus Announces Second Quarter 2025 Financial Results

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

Acquisition strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to long-term revenue and cash flow growth and further diversifying revenue base Acquisition strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to long-term revenue and cash flow growth and further diversifying revenue base

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), with respect to Supernus' proposed acquisition of Sage Therapeutics, Inc., a Delaware corporation (NASDAQ: SAGE) ("Sage"), expired at 11:59 p.m. Eastern Time on July 25, 2025.

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025

ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2025 after the market closes on Tuesday, August 5, 2025.

Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sage Therapeutics, Inc. (NasdaqGM: SAGE) to Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN). Under the terms of the proposed transaction, Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable upon.

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sage Therapeutics, Inc. (NasdaqGM: SAGE) to Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN). Under the terms of the proposed transaction, Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable upon.

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

See News Rankings

Charts implemented using Lightweight Charts™